Skip to search formSkip to main contentSkip to account menu

Panzem

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

2-methoxyestradiol

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
Phase II study of 2-methoxyestradiol NanoCrystal dispersion (2ME2) alone and in combination with sunitinib (SU) in patients with metastatic renal cell carcinoma (mRCC) progressing on SU.
e16116 Background: Panzem NCD (2ME2) is a non-estrogenic derivative of estradiol with antiproliferative and antiangiogenic… 
2007
2007
Phase II open-label, safety, pharmacokinetic and efficacy study of Panzem® NCD administered orally to patients with ovarian cancer
A14 Background: 2-methoxyestradiol (2ME2; Panzem ® ) inhibits tumor cell proliferation and induces apoptosis by inhibiting… 
2006
2006
Antiangiogenic effect of oral 2-methoxyestradiol on choroidal neovascularization in mice.
2005
2005
2-Methoxyestradiol (2-ME2, Panzem®) and its new derivatives inhibited lung cancer cells in vitro and in vivo
3415 2-Methoxyestradiol (2ME2, Panzem®) is an endogenous metabolite of estradiol that effectively inhibits a wide range of cancer… 
2005
2005
PD-006 2-Methoxyestradiol (2-ME2, Panzem®) and its new derivatives inhibited lung cancer cells in vitro and prolonged survivals in athymic nude rats with orthotopic lung tumors in vivo
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)